Entecavir Market

Entecavir, an oral deoxyguanosine drug, was created by Bristol-Myers Squibb and was endorsed to enter the market by the FDA in March 2005. Entecavir made by Sino-American Shanghai Squibb Drugs Ltd got CFDA's sanction toward the conclusion of 2005 and entered the Chinese market in mid-2006, trailed by numerous nonexclusive medications that prompted the early market evolution improbably.

Entecavir has better and speedier antiviral effect and perceives less resistance from other prescription when compared to ordinary nucleoside analogs are known to have. Endorsing a high genetic barrier to resistance, it is an impressive and long-acting HBV substance for basic monotherapy. As the demand for HBV drugs is far from being met, China's entecavir market is concentrated to have promising deals prospects in the coming years.

As per the report, because of the lesser supply of new antiviral medications for Hepatitis B, the market request is a long way from being fulfilled. Thus, entecavir is assessed to reckon great market possibilities and prompting growth of related industries namely medical and healthcare industry. In any case, because of the decrease in normal costs, trade of entecavir in the Chinese market may keep on declining as anticipated.

For World Hepatitis Day 2020, WHO is fixated on the theme “Hepatitis-Free Future” to highlight the importance of addressing the prevention of mother-to-child transmission of HBV, establish new guidance, and to call for altered domestic and international programming and funding to prevent hepatitis B mother-to-child transmission and expand admittance to hepatitis prevention, testing and treatment services, with a view to achieving the 2030 elimination targets. Entecavir made by Sino-American Shanghai Squibb Drugs Ltd rules the Chinese market with a share of more than 40% in 2019 in terms of deals value. Asia Pacific is anticipated to record higher progression rate in entecavir market during the assessment year 2022-2032.

Global Entecavir Market Value Share Analysis, by Geography (2021)

The report titled “Global Entecavir Market - Global Market Share, Trends, Analysis and Forecasts, 2022-2032”, wherein 2020 is historic period, 2021 is the base year, and 2022 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global entecavir market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market.

The global entecavir market is segmented based on product type, and end user type, and region. Based on product type is segmented into Injection type, Freeze-dried powder type, other types etc. Based on end user type is segmented into Personal, Hospital user, Clinic user, others user, etc. Based on geography is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America is sub-segmented into the United States, Canada, and Rest of North America. Europe is sub-segmented into Germany, United Kingdom, Italy, France, Spain, and Rest of Europe. Asia Pacific is sub-segmented into China, Japan, India, Australia, and Rest of Asia Pacific. Middle East & Africa is sub-segmented into Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa. South America is sub-segmented into Brazil and Rest of South America.

The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment and would identify the segment of the company focusing on global entecavir market. Further, market share of prominent companies in the global entecavir market would also be estimated. 

The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, swot analysis, and research and development focus of all the entecavir companies. The global entecavir market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution. Product portfolio would focus on all the products under the entecavir business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global entecavir market.

The key players of the global entecavir market are Avanscure Lifesciences Pvt, Mylan, Novartis, Jiangxi Qingfeng Pharmacy Co., Ltd, Tynitrix health pharmaceutical, Haisco Pharmaceutical, Qingfeng Pharmaceutical, Hainan Zhonghe Pharmaceutical, Dawnrays Pharmaceutical Limited, Invitrogen, GSK, Bristol-Myers Squibb, Pfizer, Swords Laboratories, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Sino-American Shanghai Squibb Pharmaceuticals Ltd, Abbott, Takeda, Fujian Cosunter Pharmaceutical Co., Ltd, others.

Global Entecavir Market Key Segments:

By Product type

• Injection type
• Freeze-dried powder type
• Other types

By End user type

• Personal Hospital user
• Clinic user
• Others user

By Region

• North America
  • U.S.
  • Canada
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of APAC
• Middle East & Africa
  • UAE
  • South Africa
  • Saudi Arabia
  • Rest of MEA
• South America
  • Brazil
  • Rest of South America